Alemtuzumab CARE-MS II 5-year follow-up

@inproceedings{Coles2017AlemtuzumabCI,
  title={Alemtuzumab CARE-MS II 5-year follow-up},
  author={Alasdair John Coles and Jeffrey A. Cohen and Edward J. Fox and Gavin Giovannoni and H C Hartung and Eva Kubala Havrdov{\'a} and Sven Schippling and Krzysztof W. Selmaj and Anthony Traboulsee and D. Alastair S. Compston and David H. Margolin and Karthinathan Thangavelu and Madalina C. Chirieac and Darlene Jody and Panos Xenopoulos and Richard J. Hogan and Michael A. Panzara and Douglas L. Arnold},
  booktitle={Neurology},
  year={2017}
}
OBJECTIVE To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS In the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II study (NCT00548405), alemtuzumab-treated patients received 2 courses (baseline and 12 months later). Patients could enter an extension (NCT00930553), with as-needed alemtuzumab retreatment for relapse or MRI activity… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations